# Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy

> **NCT03680261** · PHASE3 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 556 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **RADIATION:** chemoradiotherapy
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT03680261
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 556 (ESTIMATED)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03680261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03680261, "Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03680261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*